Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4

Inclusion criteria

• Chinese healthy male adult subjects aged 18-45 years old
• Body mass index [BMI between 19.0-24.0 kg/m2
• Hemoglobin A1c (HbA1c)≤6%

Exclusion criteria

• Abnormalities that were assessed by the investigators to be clinically significant at screening included vital signs, physical examination, laboratory testing, anteroposterior and lateral chest radiography, and 12-lead ECG
• Known severe allergies (e.g., allergy to more than 3 allergens, allergic asthma affecting the lower respiratory tract, allergy requiring glucocorticoid treatment) or known allergic history to the ingredients of the investigational drug used in this study
• Participants had donated blood ≥ 200 mL within 6 months before screening, or had donated blood components, or had a total blood loss of ≥ 200 mL due to any reason, or history of blood transfusion or use of blood products
• Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or treponema pallidum antibody positive
• Participated in other clinical trials and used investigational drugs or medical devices within 3 months before screening